Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

Similar presentations


Presentation on theme: "Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified."— Presentation transcript:

1 Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified by expired carbon monoxide (except week 36 which was a telephone visit). Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified by expired carbon monoxide (except week 36 which was a telephone visit). Modified from [23]. Philip Tønnesen Eur Respir Rev 2013;22:37-43 ©2013 by European Respiratory Society


Download ppt "Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified."

Similar presentations


Ads by Google